Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.

× No keyword cloud information.

20 in total

1. Osteosclerotic myeloma without features of POEMS syndrome.

Authors: Toshiki Terao; Kosei Matsue
Journal: Int J Hematol Date: 2019-08-12 Impact factor: 2.490

Review 2. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.

Authors: Yasunobu Sekiguchi; Kunimoto Ichikawa; Mutsumi Wakabayashi; Keiji Sugimoto; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal: Int J Clin Exp Pathol Date: 2015-08-01

3. A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents.

Authors: Roberto Ria; Antonia Reale; Michele Moschetta; Giuseppe Mangialardi; Franco Dammacco; Angelo Vacca
Journal: Int J Clin Exp Med Date: 2012-11-18

4. Bone anabolic agents for the treatment of multiple myeloma.

Authors: Sonia Vallet; Noopur Raje
Journal: Cancer Microenviron Date: 2011-12-03

5. Engineered nanomedicine for myeloma and bone microenvironment targeting.

Authors: Archana Swami; Michaela R Reagan; Pamela Basto; Yuji Mishima; Nazila Kamaly; Siobhan Glavey; Sufeng Zhang; Michele Moschetta; Dushanth Seevaratnam; Yong Zhang; Jinhe Liu; Masoumeh Memarzadeh; Jun Wu; Salomon Manier; Jinjun Shi; Nicolas Bertrand; Zhi Ning Lu; Kenichi Nagano; Roland Baron; Antonio Sacco; Aldo M Roccaro; Omid C Farokhzad; Irene M Ghobrial
Journal: Proc Natl Acad Sci U S A Date: 2014-06-30 Impact factor: 11.205

Review 6. Myeloma and Bone Disease.

Authors: Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal: Curr Osteoporos Rep Date: 2017-10 Impact factor: 5.096

7. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.

Authors: E Terpos; D Christoulas; E Kastritis; M Roussou; M Migkou; E Eleutherakis-Papaiakovou; M Gavriatopoulou; M Gkotzamanidou; N Kanellias; E Manios; C Papadimitriou; M A Dimopoulos
Journal: Leukemia Date: 2013-09-18 Impact factor: 11.528

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.